InvestorsHub Logo
Followers 0
Posts 160
Boards Moderated 0
Alias Born 06/14/2004

Re: None

Tuesday, 12/14/2004 12:13:47 PM

Tuesday, December 14, 2004 12:13:47 PM

Post# of 11
Tm Bioscience Appoints Cytogenetics Expert
- Company Augments Scientific Advisory Board to Target Broader Markets -

TSX: TMC

TORONTO, Dec. 14 /CNW/ - Tm Bioscience Corporation (Toronto, Ontario;
TSX: TMC), an emerging leader in the commercial genetic testing market, today
announced the appointment of Dr. Daynna Wolff, Director of the Cytogenetics
and Molecular Pathology Laboratories at the University of South Carolina, to
the Company's Scientific Advisory Board (SAB). Dr. Wolff will be a key advisor
supporting the Company's efforts to develop and commercialize diagnostic tests
for cytogenetic disease states, caused by numerical and structural chromosome
abnormalities.
"We have identified several opportunities where our Universal Array
technology could result in products which more rapidly and cost effectively
identify and characterize cytogenetic disease states in a clinical setting,
leading to improved treatment responses. Dr. Wolff is a leading expert in
cytogenetics and will be invaluable as we select our first products to develop
for this large, underserved market," said Greg Hines, President and CEO of
Tm Bioscience. "She will also be the second member of our SAB to hold a
position with the American College of Medical Genetics, which develops
guidelines for genetic testing in the US."
"Currently, virtually all routine clinical cytogenetic analysis involves
procedures that are highly complex and labour intensive, requiring trained
staff to make visual examinations of patient samples via microscopy," said
Dr. Wolff. "The technologies Tm has developed provide the unprecedented
opportunity to create accurate, high throughput and largely automated
diagnostic tools to evaluate chromosomes."
Dr. Daynna Wolff is an Associate Professor of Pathology and Laboratory
Medicine at the University of South Carolina where she is the Director of the
Cytogenetics and Molecular Pathology laboratories. She received her
certification in Clinical Cytogenetics and Clinical Molecular Genetics by the
American Board of Medical Genetics in 1996. Dr. Wolff is a member of the Board
of Directors for the American College of Medical Genetics, is the
Hematopathology representative to the Clinical Practice Committee of the
Association of Molecular Pathology, is a member of the Cytogenetic Resource
Committee of the College of American Pathologists, is a member of the Center
for Disease Control's Resource Committee for Developing Quality Control
Materials for Genetic Testing and serves on several local and departmental
committees and advisory boards.
Dr. Wolff earned her B.A. from the College of Notre Dame of Maryland,
Baltimore in 1985 and a Ph.D. from the Division of Human Genetics, University
of Maryland at Baltimore in 1991. She subsequently completed a post-doctoral
Fellowship in the Department of Genetics at Stanford University and was a
Clinical Cytogenetics and Clinical Molecular Genetics Fellow at the Center for
Human Genetics in Cleveland, Ohio from 1993-1995.

About Tag-It(TM) genetic tests
Tm Bioscience's product menu is focused in the fields of human genetic
disorders, pharmacogenetics and infectious disease. The Company has already
commercialized a series of Tag-It(TM) tests for coagulation genes (Factor V,
Factor II, MTHFR)(*), Cystic Fibrosis gene (CFTR 40+4(*) and ASR(xx) format),
and drug metabolism genes (Tag-It(TM) P450-2D6, P450-2C9, P450-2C19)(*). All
genetic tests from Tm Bioscience are based on the Tag-It(TM) Universal Array
platform, which utilizes a proprietary universal tag system that allows for
easy optimization, product development and expansion. Assays from Tm operate
on the Luminex xMAP(R) system, a well established bead based instrument.
Combined, the Universal Array and Luminex instrument enable the rapid
production of flexible, highly accurate, high-throughput, low-cost DNA-based
tests.

(*) For Research Use Only. Not for use in diagnostic procedures.
(xx)Analyte Specific Reagent. Analytical and performance characteristics
are not established.

About Tm Bioscience - Putting the Human Genome to Work(TM)
Tm Bioscience is a DNA-based diagnostics company developing a suite of
genetic tests. Tm Bioscience's product pipeline includes tests for genetic
disorders, drug metabolism, and infectious diseases. Tm Bioscience is located
in Toronto, Ontario. Additional information about Tm Bioscience can be found
at www.tmbioscience.com.

The TSX Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.




Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.